Egypt Pharmaceuticals & Healthcare Report Q4 2013 - New Market Study Published
We continue to expect that Egypt's pharmaceutical market will experience negative shorterterm issues on account of the protracted political turmoil. We also note that the cost of imports - of both pharmaceutical raw materials and finished products - will rise following the recent downgrade of Egypt's credit rating. Nevertheless, in the longer term, we still expect steady growth of both values and volumes, as the market's underlying characteristics - including growing population and gradually improving access to facilities - promote...
View full press release